These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8694538)

  • 1. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
    Schuurman JJ; Bong SB; Einarsson R
    Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
    Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.
    Einarsson R; Lindman H; Bergh J
    Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
    Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
    Zheng H; Luo RC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
    Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
    Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
    Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
    Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients.
    Cohen AD; Gopas J; Karplus G; Cohen Y
    Isr J Med Sci; 1995; 31(2-3):155-9. PubMed ID: 7744585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
    Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
    Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA.
    Willsher PC; Beaver J; Blamey RW; Robertson JF
    Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC; Day W; Jones B; Loo WT; Chow LW
    Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical importance of determination of tumor markers during follow-up in breast carcinoma].
    Fínek J; Holubec L; Topolcan O; Pikner R; Sůvová B; Treska V
    Cas Lek Cesk; 2004; 143(3):174-7. PubMed ID: 15134036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
    Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
    J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of serum S100 protein and tissue polypeptide-specific antigen for diagnosis and treatment of breast cancer].
    Luo RC; He XB; Cai HB; Li AM
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Jan; 24(1):102-4. PubMed ID: 14724113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
    Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
    Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How can treatment response be measured in breast cancer patients?
    van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB
    Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.